Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia

Lignende værker

• Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
  af: Xu, Zhenshu, et al.
  Udgivet: (2009)
• Altered intracellular signaling by imatinib increases the anti‐cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells
  af: Hirao, Takuya, et al.
  Udgivet: (2017)
• Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees
  af: Chow, Eric J., et al.
  Udgivet: (2020)
• SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells
  af: Bu, Qiangui, et al.
  Udgivet: (2014)
• Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors
  af: Bloudek, Lisa M., et al.
  Udgivet: (2015)